Ubs Group Ag Gamida Cell Ltd. Call Options Transaction History
Ubs Group Ag
- $397 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GMDA
# of Institutions
58Shares Held
11.4MCall Options Held
235KPut Options Held
70.5K-
Levin Capital Strategies, L.P. New York, NY3.75MShares$112,4280.01% of portfolio
-
Meitav Dash Investments LTD3.24MShares$97,1260.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT800KShares$24,0000.0% of portfolio
-
Stone X Group Inc.794KShares$23,8180.0% of portfolio
-
Qube Research & Technologies LTD London, X0298KShares$8,9340.0% of portfolio
About Gamida Cell Ltd.
- Ticker GMDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,319,600
- Market Cap $2.29M
- Description
- Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...